NasdaqCM - Nasdaq Real Time Price USD

MiMedx Group, Inc. (MDXG)

6.36

+0.07

(+1.11%)

At close: April 22 at 4:00 PM EDT

6.36

0.00

(0.00%)

After hours: April 22 at 4:18 PM EDT

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webc

GlobeNewswire 6 days ago
MDXG: Legal Avenues

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Since the report of 2023 full year results on February 28th, MiMedx Group, Inc. (NASDAQ:MDXG) has received an update on its request for designation for Axiofill from the FDA. It has also signed a commercialization agreement with TELA Bio to distribute xenograft products, introduced an e-commerce and account management

Zacks Small Cap Research 11 days ago
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administratio

GlobeNewswire 26 days ago
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating woundsMARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xen

GlobeNewswire last month
MIMEDX Introduces E-Commerce and Account Management Platform

Designed to Streamline Ordering, Payment Processing, and Reimbursement SubmissionsMARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of MIMEDX Connect™, an online product ordering and account management portal available to its customers through the Company’s website. “In our ongoing commitment to improve our customers’ experience, we are excited to introduce the MIMEDX Connect platform, which is designed to s

GlobeNewswire last month
MIMEDX Announces Appointment of Two New Independent Directors

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors

GlobeNewswire last month
MDXG: Another Beat & Raise

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT 2023 Financial and Operational Summary MiMedx Group, Inc. (NASDAQ:MDXG) reported full year 2023 revenues of $321.5 million, representing a 20% year over year growth rate, surpassing our $320 million estimate. Pre-tax income was $30.6 million, benefiting from lower expenses on every line. A tax benefit was recognized,

Zacks Small Cap Research last month
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth

GlobeNewswire last month
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024Presentation: Monday, March 4, 2024 at 2:10 PM ETWebcast: Click here to access Institutional investors interested in meeting with senior management may contact their TD Cowen representative. A live webcast of the presentation will be availabl

GlobeNewswire 2 months ago
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the follo

GlobeNewswire 2 months ago
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic PrioritiesMARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of the Company’s future growth objectives. These new senior secured credit facilities (the “Facili

GlobeNewswire 2 months ago
MDXG: Axiofill Update & Series B Conversion

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Corporate Updates MiMedx Group, Inc. (NASDAQ:MDXG) has updated investors on two important events over the last few weeks. Most recently, the company announced that the FDA issued a Warning Letter related to Axiofill’s classification as a Section 361 product. Recall that Axiofill was launched in Fall of 2022 as an acellular

Zacks Small Cap Research 3 months ago
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net Sales Growth in the High Teens and Fourth Quarter Adjusted EBITDA Margin of Above 20% MARIETTA, Ga., Dec. 29, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net

GlobeNewswire 3 months ago
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock

MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into shares of the Company’s Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company’s Articles of Incorporation. As a result of this conversion, approximatel

GlobeNewswire 3 months ago
MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum Capital Group 14th Annual Alpha Select Conference Thursday, November 16, 2023Sheraton New York Times Square Hotel811 7th Avenue, W 53rd St New York, NY Mizuho Medical Device & Healthcare Services Summit 2023Wednesday, December 6, 2023Sofitel New York45 W 44th StNew

GlobeNewswire 5 months ago
MIMEDX to Highlight Published Data at SAWC Fall

Company Will Sponsor Lunch Symposium on November 3, 2023MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV. In addition, the Company will participate in the conference’s exhibition at booth number 511. In the session, Drs. Mouawad, Tettelbach, and Wahab will review r

GlobeNewswire 5 months ago
MDXG: Xenografts and Synthetics Options for Expansion

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Third Quarter 2023 Summary MiMedx Group, Inc. (NASDAQ:MDXG) reported third quarter 2023 revenues of $81.7 million, representing a 21% year over year growth rate, surpassing our $76.4 million estimate. Net income was $8.5 million, benefitting from lower expenses on every line. Management firmed up revenue growth guidance for

Zacks Small Cap Research 5 months ago
MIMEDX Announces Third Quarter 2023 Operating and Financial Results

Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, Ga., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the quarter ended September 30, 2023. Recent Operating and Financial Highlights: Third quarter 2023 net sales of $81.7 million, an increase of 20.7% over third quarter 2022.

GlobeNewswire 5 months ago
MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30

MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, October 30, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information:

GlobeNewswire 6 months ago
MIMEDX Announces Launch of EPIEFFECT™

Adds to Company’s Broad Portfolio of Advanced Wound Care (“AWC”) ProductsMARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company’s core AWC offering for clinicians treating acute and chronic, hard-to-heal wounds such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), among other common condit

GlobeNewswire 6 months ago

Performance Overview

Return	MDXG	S&P 500
YTD	-27.48%	+5.05%
1-Year	+69.60%	+21.22%
3-Year	-39.43%	+20.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MiMedx Group, Inc. (MDXG)

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MDXG: Legal Avenues

MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

MIMEDX Introduces E-Commerce and Account Management Platform

MIMEDX Announces Appointment of Two New Independent Directors

MDXG: Another Beat & Raise

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

MDXG: Axiofill Update & Series B Conversion

MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook

MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Highlight Published Data at SAWC Fall

MDXG: Xenografts and Synthetics Options for Expansion

MIMEDX Announces Third Quarter 2023 Operating and Financial Results

MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30

MIMEDX Announces Launch of EPIEFFECT™

Performance Overview